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Atherosclerosis – the pathophysiological mechanism shared by most cardiovascular diseases – 97 
can be directly or indirectly assessed by a variety of clinical tests including measurement of 98 
carotid intima-media thickness, carotid plaque, ankle-brachial index, pulse wave velocity, and 99 
coronary artery calcium. The Prospective Studies of Atherosclerosis (Proof-ATHERO) 100 
Consortium (https://clinicalepi.i-med.ac.at/research/proof-athero/) collates de-identified 101 
individual-participant data of studies with information on atherosclerosis measures, risk factors 102 
for cardiovascular disease, and incidence of cardiovascular diseases. It currently comprises 74 103 
studies that involve 106,846 participants from 25 countries and over 40 cities. 21 studies 104 
recruited participants from the general population (n=67,784), 16 from high-risk populations 105 
(n=22,677), and 37 as part of clinical trials (n=16,385). Baseline years of contributing studies 106 
range from April 1980 to July 2014; the latest follow-up was until June 2019. Mean age at 107 
baseline was 59 (standard deviation: 10) years and 50% were female. Over a total of 830,619 108 
person-years of follow-up, 17,270 incident cardiovascular events (including coronary heart 109 
disease and stroke) and 13,270 deaths were recorded, corresponding to cumulative incidences 110 
of 2.1% and 1.6% per annum. The consortium is coordinated by the Clinical Epidemiology 111 
Team at the Medical University of Innsbruck, Austria. Contributing studies undergo a detailed 112 
data cleaning and harmonisation procedure before being incorporated in the Proof-ATHERO 113 
central database. Statistical analyses are being conducted according to pre-defined analysis 114 
plans and use established methods for individual-participant data meta-analysis. Capitalising 115 
on its large sample size, the multi-institutional collaborative Proof-ATHERO consortium aims 116 
to better characterise, understand, and predict the development of atherosclerosis and its clinical 117 
consequences.  118 
 119 
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Cardiovascular diseases (CVD) are the most common cause of death and disability worldwide. 123 
According to recent estimates from the Global Burden of Disease Study, about 18 million 124 
people die of CVD in a year, which account for over 30% of all global deaths [1]. The 125 
pathophysiological mechanism shared by many CVD is atherosclerosis, a gradual and 126 
progressive hardening and narrowing of the arteries over the course of life. Initial 127 
atherosclerotic alterations can be found as early as in young adulthood [2, 3] and involve 128 
endothelial dysfunction, inflammation, and deposition of fat [4]. Advanced atherosclerotic 129 
lesions are characterised by formation of atherosclerotic plaque that can destabilise, rupture or 130 
fissure, and can ultimately lead to acute vessel occlusion or formation of a local thrombus with 131 
dislocation into distal arteries and thereby clinical sequelae [4].  132 
Clinical and subclinical atherosclerosis can be directly or indirectly assessed using a 133 
range of different clinical tests which are simple, safe, and non-invasive, and therefore 134 
amenable for use in large-scale studies (Fig. 1). One of the imaging techniques for 135 
atherosclerosis most frequently used is the assessment of carotid intima-media thickness 136 
(cIMT). Using B-mode high-resolution ultrasound, the distance between the intimal and medial 137 
layer of the carotid arterial wall is quantified. Spatial resolution of this imaging technique is 138 
approximately 50 µm axially and 200 µm laterally. Ultrasound-based cIMT is considered as a 139 
marker of the early stage of atherosclerosis. It is related to unfavourable levels of traditional 140 
cardiovascular risk factors [5, 6] and has been shown to be in good accordance with “true” 141 
cIMT determined in histological studies [7]. Furthermore, increased cIMT has been associated 142 
with increased risk of cardiovascular events [8, 9]. 143 
Other scalable and commonly available measures to ascertain vessel wall pathology and 144 
dysfunction include the carotid plaque [10, 11], ankle-brachial index [12], pulse wave velocity 145 
[13], and coronary artery calcium [14–16] (Fig. 1). As reviewed recently [17], these measures 146 
have several strengths and weaknesses. cIMT, carotid plaque, ABI, and PWV are non-invasive 147 
and cost-effective markers, which are therefore relatively easy to implement in large clinical 148 
studies. However, disadvantages include measurement error and lack of standardisation in 149 
measurement protocols for cIMT, specificity of ABI [12], and the error associated with the 150 
measurement of travelled distance for PWV [18]. Coronary artery calcium directly quantifies 151 
presence of calcification in coronary arteries [19]. In contrast to the other mentioned markers, 152 
coronary artery calcification is assessed with computed tomography, which is more costly and 153 




According to the 2019 European Society of Cardiology Guidelines for the diagnosis and 155 
management of chronic coronary syndromes, atherosclerotic plaque detection by carotid artery 156 
ultrasound, assessment of coronary artery calcium score with computed tomography, and 157 
measurement of the ankle-brachial index may be considered as risk modifiers in cardiovascular 158 
risk assessment in asymptomatic subjects [19]. Because atherosclerosis typically develops over 159 
a long period of time and only causes symptoms at an advanced stage, these measures are 160 
important tools in clinical practice to quantify atherosclerosis burden and might help inform 161 
treatment decisions.  162 
The Prospective Studies of Atherosclerosis (Proof-ATHERO) consortium is an 163 
international consortium that brings together individual-participant data from prospective 164 
cohorts with detailed information on atherosclerosis, covariates, and incidence of CVD 165 
outcomes. The present report provides a description of broad aims of the Proof-ATHERO 166 
consortium and the principal methodology involved in collating, harmonising, and analysing 167 
study data.  168 
Design 169 
Objectives 170 
Capitalising on its large sample size and the comprehensive information available, the 171 
overarching aims of the Proof-ATHERO consortium are to: (i) better characterise the natural 172 
history, communalities, and differences of different atherosclerosis measures; (ii) to provide 173 
novel insight into the determinants of atherosclerosis development and progression; and (iii) to 174 
investigate clinical consequences of atherosclerosis. In contrast to prior reports in individual 175 
studies, the large-scale data of Proof-ATHERO enables the study team to conduct power-176 
demanding analyses, including (i) characterisation of atherosclerosis trajectories over time; (ii) 177 
determination of the shapes of associations (e.g. linear vs. curvilinear vs. threshold effects); (iii) 178 
study of potential effect modifiers (e.g. age, sex, or medication, or different lifestyle factors 179 
such as smoking habit); (iv) direct comparisons of the added predictive value of different 180 
atherosclerosis measures over and beyond assessment of conventional risk factors; and (v) 181 
reliable evaluation of atherosclerosis measures as surrogate markers for clinically manifest 182 
CVD endpoints. Overall, Proof-ATHERO aims to analyse world-wide available data to deliver 183 




Inclusion criteria 185 
Prospective cohorts are eligible for inclusion in the Proof-ATHERO consortium if they were 186 
observational studies or clinical trials that: (i) have assessed one or more atherosclerosis 187 
measures (i.e. cIMT, carotid plaque, ankle-brachial index, pulse wave velocity, and coronary 188 
artery calcium) repeatedly (i.e. at two or more time points); (ii) have ascertained comprehensive 189 
information on CVD risk factors (e.g. lifestyle, blood-based markers, history of disease, and 190 
medication intake); and (iii) have recorded incident CVD outcomes using well-defined criteria.   191 
 A crucial foundation for the Proof-ATHERO consortium was provided by the PROG-192 
IMT project [20]. This initiative led by Matthias Lorenz at the Goethe University at Frankfurt 193 
am Main had collated and analysed individual-participant data on the progression of cIMT and, 194 
for instance, yielded milestone publications on the association of cIMT progression with future 195 
CVD risk in the general population [8], in people with type-2 diabetes [21], and in people at 196 
high cardiovascular risk [22]. When the PROG-IMT project was completed in 2017, a majority 197 
of contributing studies (83%) decided to continue the fruitful collaboration as part of the Proof-198 
ATHERO consortium and to jointly investigate scientific questions which go beyond the initial 199 
aims of the PROG-IMT project. The commitment by these studies gave a unique head-start to 200 
the Proof-ATHERO consortium and enabled efficient data accrual at the beginning of the 201 
initiative. 202 
 Identification and incorporation of new eligible studies is ongoing and we invite 203 
researchers to contact the coordinating centre if they wish to contribute to the Proof-ATHERO 204 
consortium. 205 
Atherosclerosis measures 206 
Data have been sought from investigators on carotid ultrasound parameters, ankle-brachial 207 
index, pulse wave velocity, and coronary artery calcium at baseline and any subsequent re-208 
examinations during follow-up. Atherosclerosis measures assessed by the individual studies are 209 
summarised in Table 1. Parameters based on carotid ultrasound are being collected 210 
systematically on up to twelve sites (common carotid artery, carotid bifurcation, and internal 211 
carotid artery; left and right side; near and far wall) and include cIMT, vessel diameter, presence 212 
of plaques (yes vs. no), number of plaques, plaque thickness (height in mm), plaque area in a 213 
longitudinal view (in mm2), and plaque morphology according to the Gray-Weale classification 214 
[23]. The methodologies which studies used to cIMT and carotid plaque are summarised in 215 




Participant characteristics at the baseline and follow-up surveys 217 
Data on participant characteristics at baseline and follow-up surveys have been sought from 218 
investigators on age, sex, ethnicity, socio-economic status, smoking, systolic and diastolic 219 
blood pressure, body-mass index, lipid markers (e.g. total cholesterol, high- and low-density 220 
lipoprotein cholesterol, triglycerides), markers of inflammation (e.g. C-reactive protein, 221 
fibrinogen, leukocyte count), markers of dysglycaemia (e.g. fasting glucose, glycated 222 
haemoglobin), use of medication (e.g. antihypertensive, antidiabetic, lipid-lowering 223 
medication), and pre-existing diseases (e.g. coronary heart disease, stroke, diabetes, or 224 
hypertension). Furthermore, in clinical trials, information on the type of interventions (and 225 
dosages, if appropriate) and on adherence to allocated regimens have been collated.  226 
Incident disease outcomes  227 
Data on incident disease outcomes have been collated predominantly on fatal and non-fatal 228 
CVD events, including myocardial infarction, angina pectoris, and subtypes of stroke. A 229 
detailed description of ascertainment and classification of prevalent and incident CVD is 230 
provided in Table S4. Studies assessed prevalent CVD at study baseline using self-report only 231 
or supplemented by objective criteria. The vast majority of the studies used objective criteria 232 
rather than self-report only for assessing incident coronary heart disease (93%) and incident 233 
stroke (90%). In addition, information on cause-specific death has been sought. In 15 studies, 234 
cause of death was ascertained based on the death certificate; 44 studies supplemented the death 235 
certificate with information from additional sources (e.g. medical records, autopsy findings). 236 
Studies assessed prevalent CVD at study baseline using self-report only or supplemented by 237 
objective criteria. A detailed description of ascertainment and classification of prevalent and 238 
incident CVD is provided in Table S4. 239 
Coordination of the consortium 240 
The Proof-ATHERO consortium is coordinated by the Clinical Epidemiology team at the 241 
Medical University of Innsbruck, Austria. An outline of the processes involved in Proof-242 
ATHERO coordination is provided in Fig. 2. Standardised data request forms are sent to eligible 243 
studies, inviting them to participate in the initiative. Upon receipt of study data, data cleaning 244 
and harmonisation are performed by a dedicated data management team using a range of tools 245 
for detecting inconsistencies and ambiguities in the data. Any queries arising during this process 246 




data management process, study data are stored in a central database at the coordinating centre. 248 
The data management system of the coordinating centre has been implemented in SAS 9.4. 249 
Proposals for analyses can be submitted by all members of the Proof-ATHERO study group 250 
(i.e. all named investigators of studies contributing data to Proof-ATHERO) via the 251 
consortium’s webpage. Upon receipt, proposals are reviewed by a dedicated Proof-ATHERO 252 
steering committee, which then allocates resources at the coordinating centre according to 253 
resource availability and scientific priority of the project. For contractual reasons, data are 254 
stored and analysed exclusively at the Proof-ATHERO Coordinating and Statistics Centres 255 
(Medical University of Innsbruck and University of Cambridge). At each step from 256 
development of a statistical analysis plan, to the conduct of statistical analyses, and the creation 257 
of a manuscript draft, investigators of contributing studies and expert panels are contacted for 258 
feedback and comments, therefore making use of the broad and diverse community of experts 259 
in the field involved in the initiative.  260 
General approach to statistical analyses 261 
For each scientific project, statistical analyses will be performed according to a pre-specified 262 
analysis plan. Statistical analyses will follow established methods in the analysis of individual-263 
participant data [24–29]. Generally, the multi-level structure of data (e.g. multiple cohorts) will 264 
be taken into account by combining study-specific estimates using meta-analytical methods or 265 
by using mixed regression models with appropriate specification of random effects. Analyses 266 
will also involve assessments of between-studies heterogeneity. More details on specific 267 
analytical methods will be provided in publications resulting from each scientific project. 268 
Data protection and ethics considerations 269 
All studies contributing data to Proof-ATHERO have previously reported results and have 270 
obtained relevant local ethics approval and participants’ consent. The data provided by each 271 
study remain entirely the property of the principal investigators of that study and are held in 272 
confidence by the Proof-ATHERO coordinating centre. To safeguard the identity of individuals 273 
at all stages of the analysis and to ensure compliance with data protection legislation and 274 
confidentiality guidelines, study data are transferred to the coordinating centre using encrypted 275 
connections.  De-identified data are being stored securely in a central database at the 276 




and collaborating studies have the right to withdraw from the Proof-ATHERO consortium at 278 
any time and without giving reasons. 279 
Characteristics of contributing studies 280 
As of 24 January 2020, a total of 74 studies involving 106,846 participants are part of the Proof-281 
ATHERO consortium. The designs of contributing studies and key study-level characteristics 282 
are shown in Table 2. In summary, 21 studies recruited participants from the general 283 
population, 16 studies were conducted in patient populations with specific pre-existing diseases 284 
(e.g. with diabetes), and 37 studies were randomised controlled trials covering a range of 285 
different patient populations. The numbers of people enrolled in these three types of studies 286 
were 67,784, 22,677, and 16,385, respectively. Baseline years ranged from April 1980 to July 287 
2014; the last follow-up was in June 2019. Mean age at baseline was 59 years (standard 288 
deviation: 10); 50% of participants were female. Fig. 3 demonstrates the geographical location 289 
of contributing studies. Study locations were spread across four continents and are based in 25 290 
countries and over 40 cities. The median duration of follow-up (i.e. the time from baseline to 291 
first event or end of follow-up) was 6.1 years (interquartile range: 2.7-10.4). Over a total of 292 
830,619 person-years of follow-up, 17,270 incident CVD events and 13,270 deaths were 293 
recorded, corresponding to cumulative incidences of 2.1% and 1.6% per annum, respectively. 294 
As Proof-ATHERO evolves further, up-to-date information on contributing studies are being 295 
made available on the consortium’s webpage at https://clinicalepi.i-med.ac.at/research/proof-296 
athero/. 297 
Initial set of hypotheses to be tested  298 
The large sample size and variety of data in Proof-ATHERO will enable us to test several 299 
hypotheses that are particularly power-hungry and could therefore not be addressed by previous 300 
studies. For instance, it is unclear whether cIMT progression could serve as a surrogate marker 301 
for hard cardiovascular outcomes in clinical trials [30–32]. Second, given conflicting results of 302 
prior individual studies [33–39], the comparative predictive value of cIMT measurements at 303 
different locations of the carotid artery remains to be determined in detail. Third, building on 304 
the initial insights of our recent literature-based meta-analysis [40], Proof-ATHERO will 305 
characterise in detail the association of cIMT with long-term risk of developing carotid plaque. 306 




consistent approach to statistical analysis and outcome definitions of Proof-ATHERO will help 308 
to address the aforementioned and other questions with reliably than previously possible. 309 
Strengths and limitations 310 
Proof-ATHERO is a large consortium with a huge amount of data on atherosclerosis applying 311 
consistent approaches to data harmonisation and analysis. By inclusion of data from 25 312 
countries and different clinical settings, the generalisability of findings will be of particular 313 
value. Our study also has several limitations. First, there were some differences between studies 314 
in how they assessed atherosclerosis measures and clinical outcomes. To address this issue, we 315 
collect meticulously a variety of study-specific characteristics, enabling us to quantify and 316 
better understand the impact of these differences in future analyses. Second, comprehensive 317 
data cleaning and harmonisation is a serious, often underestimated challenge. However, we 318 
managed to develop a sophisticated data management system that enables to transparently and 319 
effectively handle various datasets with different structures provided by the individual studies. 320 
Third, the current focus of available data lies on cIMT due to participation of multiple studies 321 
previously involved the PROG-IMT consortium [20]. Fourth, there exist several other markers 322 
for atherosclerosis, such as the assessment of endothelial function [41] with flow-mediated 323 
dilation or peripheral arterial tone, which have not been collected within Proof-ATHERO yet. 324 
Since the consortium is designed to continuously collect new data as they become available, 325 
coverage of other atherosclerosis markers will be expanded over time.   326 
Conclusion 327 
The Proof-ATHERO consortium is a multi-institutional collaborative project that is coordinated 328 
at the Medical University of Innsbruck. The consortium brings together large-scale data from 329 
prospective studies in the field of atherosclerosis. Proof-ATHERO combines data on CVD risk 330 
factors, repeat assessments of atherosclerosis, and clinical outcomes with cutting-edge data 331 
management and analytical tools. By inclusion of data from 25 countries and different clinical 332 
settings, the generalisability of findings will be of particular value. Building on these strengths, 333 
Proof-ATHERO will help to better characterise, understand, and predict the development of 334 





This manuscript was prepared using data of the Atherosclerosis Risk in Communities Study 337 
(ARIC), the Cardiovascular Health Study (CHS), the Jackson Heart Study (JHS), and the Multi-338 
Ethnic Study of Atherosclerosis (MESA) obtained from the NHLBI Biologic Specimen and 339 
Data Repository Information Coordinating Center (BioLINCC) and does not necessarily reflect 340 
the opinions or views of ARIC, CHS, JHS, MESA, or NHLBI. An anonymised individual-341 
participant data dataset from CREED was kindly provided by Prof. Zoccali, Prof. Tripepi, and 342 
Prof. Mallamaci from the Institute of Biomedicine (CNR), Clinical Epidemiology and 343 
Physiopathology of Renal Diseases and Hypertension, Reggio Calabria, Italy on the basis on 344 
their 'public use' policy. We thank the CREED group for sharing their valuable data. We are 345 
grateful to the team members of the VASCage project (FFG COMET K‐Project 843536) for 346 
their support. 347 
Disclosure Statement 348 
L. Tschiderer reports grants from the Dr.-Johannes-and-Hertha-Tuba Foundation during the 349 
conduct of the study and non-financial support from Sanofi outside the submitted work. L. 350 
Seekircher reports non-financial support from Sanofi outside the submitted work. G. 351 
Klingenschmid reports non-financial support from Sanofi and Pfizer outside the submitted 352 
work. N. Sattar reports personal fees from Amgen, AstraZeneca, Boehringer Ingelheim, Eli-353 
Lilly, Novo Nordisk, Sanofi, and Pfizer and grants from Boehringer Ingelheim outside the 354 
submitted work. S.E. Kjeldsen reports personal fees from Merck Darmstadt, MSD Whitehouse 355 
Station, Sanofi Paris, and Takeda Chicago outside the submitted work. S. Kiechl reports grants 356 
from Austrian Promotion Agency FFG outside the submitted work. G.D. Norata reports grants 357 
from Pfizer and Amgen and personal fees from Sanofi, Amgen, Alnylam, and Novartis outside 358 
the submitted work. P. Willeit reports grants from the Dr.-Johannes-and-Hertha-Tuba 359 
Foundation and the Austrian Science Fund FWF during the conduct of the study.  Other authors 360 




Funding Sources 362 
This work has been funded by the Austrian Science Fund (FWF) [P 32488] and the Dr.-363 
Johannes-and-Hertha-Tuba Foundation. Funders of individual studies contributing to the 364 
present analysis are listed on the Proof-ATHERO webpage (https://clinicalepi.i-365 
med.ac.at/research/proof-athero/studies/). 366 
Author Contributions 367 
L. Tschiderer, L. Seekircher, G. Klingenschmid, and P. Willeit are part of the coordinating 368 
centre and are responsible for data management and data analysis of the Proof-ATHERO 369 
consortium. L. Tschiderer and L. Seekircher drafted the manuscript, conducted the analyses, 370 
and interpreted the data. G. Klingenschmid interpreted the data. M. J. Sweeting provided 371 
supervision for statistical analyses. P. Willeit is responsible for the conception and design of 372 
the work, drafted the manuscript, conducted the analyses, and interpreted the data. All other 373 
authors were responsible for data acquisition. All authors revised the manuscript critically for 374 
important intellectual content approved the final version of the manuscript. 375 
 376 
Collaborators committee: Maria V. Manzi1, Costantino Mancusi1, Helmuth Steinmetz2, 377 
Matthias Sitzer2,3, Mauro Amato4, Fabrizio Veglia4, Elena Tremoli4, Samuela Castelnuovo5, 378 
Dong Zhao6, Miao Wang6, Stela McLachlan7, Moo-Sik Lee8,9, Hyun-Woong Park9, Salim 379 
Yusuf10,11, Diederick E. Grobbee12, Frank L. J. Visseren13, John J. P. Kastelein14, Wiek van 380 
Gilst15, Folkert W. Asselbergs16, Muriel P. C. Grooteman17, Peter J. Blankestijn18,  Ercan Ok19, 381 
Giuseppe Guglielmini20, Rino Migliacci21, Lena Bokemark22, Kazuo Kitagawa23, Michael 382 
Skilton24, Lisa M. Jamieson25, Oscar Beloqui26, David Preiss27, Philip C. Calder28,29, Lokpal 383 
Bhatia28,29, Pieter M. ter Wee17, Chrystosomos Dimitriadis30, Radovan Hojs31,32, Sebastjan 384 
Bevc31,32, Peter Reiss33,34, Marit G. A. van Vonderen35, Ana R. Cunha36, Mayuko Amaha37, 385 
Tsukasa Nakamura37, Tatyana Balakhonova38, Maya Safarova39, Jesse Dawson40, Peter 386 
Higgins40, Kristian Wachtell41, Sverre E. Kjeldsen41, Aleksandar Jovanovic42, Tatjana 387 
Lazarevic43, Aleksandra Araszkiewicz44, Aleksandra Uruska44, Dariusz Naskręt44, Beat 388 
Frauchiger45, Heiko Uthoff46, Kazuomi Kario47, Satoshi Hoshide47, Erik Stroes14, Edith 389 
Beishuizen48, Tadao Akizawa49, Thapat Wannarong50,51, Sophia Zoungas52, John McNeil52, 390 




Moise Desvarieux58,59, Pierre Ducimetiere60, Matthieu Plichart61,62, Hertzel C. Gerstein10,11, Ari 392 
Voutilainen63, Jussi Kauhanen63, Liliana Grigore64, Giuseppe D. Norata64,65, Ta-Chen Su66, Pei-393 
Chun Chen67, Hung-Ju Lin66, Holger Poppert68, Horst Bickel69, and M. Arfan Ikram70. 394 
 395 
Affiliations of members of the collaborators committee: 1Department of Advanced 396 
Biochemical Sciences, Federico II University, Naples, Italy; 2Department of Neurology, Goethe 397 
University, Frankfurt am Main, Germany; 3Department of Neurology, Klinikum Herford, 398 
Herford, Germany; 4Centro Cardiologico Monzino IRCCS, Milan, Italy; 5Centro Dislipidemie, 399 
ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; 6Department of Epidemiology, 400 
Beijing Anzhen Hospital, Capital Medical University, Beijing, China; 7Usher Institute, 401 
University of Edinburgh, Edinburgh, UK; 8Department of Preventive Medicine, Konyang 402 
University, Daejeon, Korea; 9College of Medicine, Konyang University Hospital, Daejeon, 403 
Korea; 10Department of Medicine and Population Health Research Institute, McMaster 404 
University, Hamilton, Ontario, Canada; 11Hamilton General Hospital, Hamilton, Ontario, 405 
Canada; 12Julius Center for Health Sciences and Primary Care, University Medical Center 406 
Utrecht, Utrecht, the Netherlands; 13Department of Vascular Medicine, University Medical 407 
Center Utrecht, Utrecht, the Netherlands; 14Department of Vascular Medicine, Academic 408 
Medical Centre, University of Amsterdam, Amsterdam, the Netherlands; 15Department of 409 
Experimental Cardiology, University Medical Center Groningen, Groningen, the Netherlands; 410 
16Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands; 411 
17Department of Nephrology, Amsterdam UMC, Amsterdam, the Netherlands; 18Department of 412 
Nephrology, University Medical Center Utrecht, Utrecht, the Netherlands; 19Division of 413 
Nephrology, Izmir Bozyaka Education and Research Hospital, Izmir, Turkey; 20Division of 414 
Internal and Cardiovascular Medicine, Department of Medicine, University of Perugia, Perugia, 415 
Italy; 21Division of Internal Medicine, Cortona Hospital, Cortona, Italy; 22Wallenberg 416 
Laboratory for Cardiovascular Research, University of Gothenburg, Gothenburg, Sweden; 417 
23Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan; 24Boden 418 
Institute of Obesity, Nutrition, Exercise and Eating Disorders, University of Sydney, Sydney, 419 
NSW 2006, Australia; 25Australian Research Centre for Population Oral Health, University of 420 
Adelaide, Adelaide, SA, Australia; 26Department of Internal Medicine, University Clinic of 421 
Navarra, Navarra, Spain; 27MRC Population Health Research Unit, Clinical Trial Service Unit, 422 
Nuffield Department of Population Health, University of Oxford, Oxford, UK; 28Faculty of 423 
Medicine, University of Southampton - Southampton General Hospital, Southampton, UK; 424 




Southampton General Hospital, Southampton, UK; 30University Department of Nephrology, 426 
Hippokration General Hospital, Thessaloniki, Greece; 31Department of Nephrology, University 427 
Medical Centre Maribor, Maribor, Slovenia; 32Faculty of Medicine, University of Maribor, 428 
Maribor, Slovenia; 33Department of Global Health, Amsterdam UMC- Location AMC, 429 
Amsterdam, the Netherlands; 34Amsterdam Institute for Global Health and Development, 430 
University of Amsterdam, Amsterdam, the Netherlands; 35Department of Internal Medicine, 431 
Medical Center Leeuwarden, Leeuwarden, the Netherlands; 36Department of Clinical Medicine, 432 
State University of Rio de Janeiro, Rio de Janeiro, Brazil; 37Division of Nephrology, 433 
Shinmatsudo Central General Hospital, Chiba, Japan; 38Ultrasound Vascular Laboratory, 434 
National Medical Research Center of Cardiology, Moscow, Russia; 39Atherosclerosis 435 
Department, National Medical Research Center of Cardiology, Moscow, Russia; 40Institute of 436 
Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK; 41Department of 437 
Cardiology, Oslo University Hospital, Oslo, Norway; 42Faculty of Medicine, University of 438 
Prishtina, Prishtina\Kosovska Mitrovica, Serbia; 43Faculty of Medicine, University of 439 
Kragujevac, Kragujevac, Serbia; 44Department of Internal Medicine and Diabetology, Poznan 440 
University of Medical Sciences, Poznan, Poland; 45Department of Internal Medicine, 441 
Kantonsspital Frauenfeld, Frauenfeld, Switzerland; 46Department of Angiology, University 442 
Hospital Basel, Basel, Switzerland; 47Department of Medicine, Jichi Medical University School 443 
of Medicine, Tochigi, Japan; 48Department of Internal Medicine, HMC+ (Bronovo), the Hague, 444 
the Netherlands; 49Division of Nephrology, Department of Medicine, Showa University School 445 
of Medicine, Tokyo, Japan; 50Stroke Prevention & Atherosclerosis Research Centre, Western 446 
University, London, Canada; 51Department of Internal Medicine, Faculty of Medicine, Siriraj 447 
Hospital, Mahidol University, Bangkok, Thailand; 52School of Public Health and Preventive 448 
Medicine, Monash University, Melbourne, Australia; 53Radiology Department, Universidad 449 
Autónoma de Madrid, Madrid, Spain; 54Internal Medicine Department, Universidad Autónoma 450 
de Madrid, Madrid, Spain; 55Department of Epidemiology & Biostatistics, Amsterdam UMC- 451 
Location Vumc, Amsterdam, the Netherlands; 56Department of General Practice, Amsterdam 452 
UMC- Location Vumc, Amsterdam, the Netherlands; 57Department of Internal Medicine and 453 
Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, 454 
Maastricht, the Netherlands; 58Department of Epidemiology, Mailman School of Public Health, 455 
Columbia University, New York, USA; 59METHODS Core, Centre de Recherche 456 
Epidémiologie et Statistique Paris Sorbonne Cité (CRESS), Institut National de la Santé et de 457 
la Recherche Médicale (INSERM) UMR 1153, Paris, France; 60Faculty of Medicine, University 458 




Paris Descartes, Paris, France; 62Assistance Publique, Hôpitaux de Paris, Hôpital Broca, Paris, 460 
France; 63Institute of Public Health and Clinical Nutrition, University of Eastern Finland, 461 
Kuopio Campus, Kuopio, Finland; 64SISA Center for the Study of Atherosclerosis, Bassini 462 
Hospital, Cinisello Balsamo, Italy; 65Department of Pharmacological and Biomolecular 463 
Sciences, University of Milan, Milan, Italy; 66Department of Internal Medicine, National 464 
Taiwan University Hospital, Taipei, Taiwan; 67Clinical Informatics & Medical Statistics 465 
Research Center, Chang Gung University, Taoyuan, Taiwan; 68Department of Neurology, 466 
Technische Universität München, Munich, Germany; 69Department of Psychiatry and 467 
Psychotherapy, Technische Universität München, Munich, Germany; 70Department of 468 





1 GBD 2017 Causes of Death Collaborators: Global, regional, and national age-sex-specific 471 
mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic 472 
analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1736–1788. 473 
2 Enos WF, Holmes RH, Beyer J: Coronary disease among United States soldiers killed in 474 
action in Korea; preliminary report. J Am Med Assoc 1953;152:1090–1093. 475 
3 McNamara JJ, Molot MA, Stremple JF, Cutting RT: Coronary artery disease in combat 476 
casualties in Vietnam. JAMA 1971;216:1185–1187. 477 
4 Libby P, Ridker PM, Hansson GK: Progress and challenges in translating the biology of 478 
atherosclerosis. Nature 2011;473:317–325. 479 
5 Ebrahim S, Papacosta O, Whincup P, Wannamethee G, Walker M, Nicolaides AN, et al.: 480 
Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent 481 
cardiovascular disease in men and women: the British Regional Heart Study. Stroke 482 
1999;30:841–850. 483 
6 Müller-Scholden L, Kirchhof J, Morbach C, Breunig M, Meijer R, Rücker V, et al.: 484 
Segment-specific association of carotid-intima-media thickness with cardiovascular risk 485 
factors - findings from the STAAB cohort study. BMC Cardiovasc Disord 2019;19:84. 486 
7 Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R: Intimal plus medial thickness of the 487 
arterial wall: A direct measurement with ultrasound imaging. Circulation 1986;74:1399–488 
1406. 489 
8 Lorenz MW, Polak JF, Kavousi M, Mathiesen EB, Völzke H, Tuomainen T-P, et al.: 490 
Carotid intima-media thickness progression to predict cardiovascular events in the general 491 
population (the PROG-IMT collaborative project): A meta-analysis of individual 492 
participant data. Lancet 2012;379:2053–2062. 493 
9 Den Ruijter HM, Peters SAE, Anderson TJ, Britton AR, Dekker JM, Eijkemans MJ, et al.: 494 
Common carotid intima-media thickness measurements in cardiovascular risk prediction: 495 
A meta-analysis. JAMA 2012;308:796–803. 496 
10 Kiechl S, Willeit J: The natural course of atherosclerosis. Part I: Incidence and progression. 497 
Arterioscler Thromb Vasc Biol 1999;19:1484–1490. 498 
11 Kiechl S, Willeit J: The natural course of atherosclerosis. Part II: Vascular remodeling. 499 




12 Fowkes FGR, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, et al.: Ankle 501 
brachial index combined with Framingham Risk Score to predict cardiovascular events and 502 
mortality: A meta-analysis. JAMA 2008;300:197–208. 503 
13 Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ, et al.: Aortic 504 
pulse wave velocity improves cardiovascular event prediction: An individual participant 505 
meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol 506 
2014;63:636–646. 507 
14 Kramer CK, Zinman B, Gross JL, Canani LH, Rodrigues TC, Azevedo MJ, et al.: Coronary 508 
artery calcium score prediction of all cause mortality and cardiovascular events in people 509 
with type 2 diabetes: Systematic review and meta-analysis. BMJ 2013;346:f1654. 510 
15 Kavousi M, Desai CS, Ayers C, Blumenthal RS, Budoff MJ, Mahabadi A-A, et al.: 511 
Prevalence and Prognostic Implications of Coronary Artery Calcification in Low-Risk 512 
Women: A Meta-analysis. JAMA 2016;316:2126–2134. 513 
16 Chaikriangkrai K, Jhun HY, Palamaner Subash Shantha G, Bin Abdulhak A, Sigurdsson 514 
G, Nabi F, et al.: Coronary artery calcium score as a predictor for incident stroke: 515 
Systematic review and meta-analysis. Int J Cardiol 2017;236:473–477. 516 
17 Vlachopoulos C, Xaplanteris P, Aboyans V, Brodmann M, Cífková R, Cosentino F, et al.: 517 
The role of vascular biomarkers for primary and secondary prevention. A position paper 518 
from the European Society of Cardiology Working Group on peripheral circulation: 519 
Endorsed by the Association for Research into Arterial Structure and Physiology 520 
(ARTERY) Society. Atherosclerosis 2015;241:507–532. 521 
18 Rajzer MW, Wojciechowska W, Klocek M, Palka I, Brzozowska-Kiszka M, Kawecka-522 
Jaszcz K: Comparison of aortic pulse wave velocity measured by three techniques: 523 
Complior, SphygmoCor and Arteriograph. J Hypertens 2008;26:2001–2007. 524 
19 Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al.: 2019 525 
ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur 526 
Heart J 2019;100:106. 527 
20 Lorenz MW, Bickel H, Bots ML, Breteler MMB, Catapano AL, Desvarieux M, et al.: 528 
Individual progression of carotid intima media thickness as a surrogate for vascular risk 529 
(PROG-IMT): Rationale and design of a meta-analysis project. Am Heart J 2010;159:730-530 
736.e2. 531 
21 Lorenz MW, Price JF, Robertson C, Bots ML, Polak JF, Poppert H, et al.: Carotid intima-532 
media thickness progression and risk of vascular events in people with diabetes: Results 533 




22 Lorenz MW, Gao L, Ziegelbauer K, Norata GD, Empana JP, Schmidtmann I, et al.: 535 
Predictive value for cardiovascular events of common carotid intima media thickness and 536 
its rate of change in individuals at high cardiovascular risk - Results from the PROG-IMT 537 
collaboration. PLoS ONE 2018;13:e0191172. 538 
23 Gray-Weale AC, Graham JC, Burnett JR, Byrne K, Lusby RJ: Carotid artery atheroma: 539 
comparison of preoperative B-mode ultrasound appearance with carotid endarterectomy 540 
specimen pathology. J Cardiovasc Surg (Torino) 1988;29:676–681. 541 
24 Thompson S, Kaptoge S, White I, Wood A, Perry P, Danesh J: Statistical methods for the 542 
time-to-event analysis of individual participant data from multiple epidemiological studies. 543 
Int J Epidemiol 2010;39:1345–1359. 544 
25 Jackson D, White I, Kostis JB, Wilson AC, Folsom AR, Wu K, et al.: Systematically 545 
missing confounders in individual participant data meta-analysis of observational cohort 546 
studies. Stat Med 2009;28:1218–1237. 547 
26 Pennells L, Kaptoge S, White IR, Thompson SG, Wood AM: Assessing risk prediction 548 
models using individual participant data from multiple studies. Am J Epidemiol 549 
2014;179:621–632. 550 
27 Sanderson J, Thompson SG, White IR, Aspelund T, Pennells L: Derivation and assessment 551 
of risk prediction models using case-cohort data. BMC Med Res Methodol 2013;13:113. 552 
28 White IR: Multivariate random-effects meta-analysis. Stata Journal 2009;9:40–56. 553 
http://www.stata-journal.com/article.html?article=st0156. 554 
29 Riley RD, Price MJ, Jackson D, Wardle M, Gueyffier F, Wang J, et al.: Multivariate meta-555 
analysis using individual participant data. Res Synth Methods 2015;6:157–174. 556 
30 Espeland MA, O'Leary DH, Terry JG, Morgan T, Evans G, Mudra H: Carotid intimal-557 
media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA 558 
reductase inhibitors. Curr Control Trials Cardiovasc Med 2005;6:3. 559 
31 Goldberger ZD, Valle JA, Dandekar VK, Chan PS, Ko DT, Nallamothu BK: Are changes 560 
in carotid intima-media thickness related to risk of nonfatal myocardial infarction? A 561 
critical review and meta-regression analysis. Am Heart J 2010;160:701–714. 562 
32 Costanzo P, Perrone-Filardi P, Vassallo E, Paolillo S, Cesarano P, Brevetti G, et al.: Does 563 
carotid intima-media thickness regression predict reduction of cardiovascular events? A 564 
meta-analysis of 41 randomized trials. J Am Coll Cardiol 2010;56:2006–2020. 565 
33 O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK: Carotid-artery 566 




adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 568 
1999;340:14–22. 569 
34 Chambless LE, Folsom AR, Clegg LX, Sharrett AR, Shahar E, Nieto FJ, et al.: Carotid wall 570 
thickness is predictive of incident clinical stroke: the Atherosclerosis Risk in Communities 571 
(ARIC) study. Am. J. Epidemiol. 2000;151:478–487. 572 
35 Lorenz MW, Kegler S von, Steinmetz H, Markus HS, Sitzer M: Carotid intima-media 573 
thickening indicates a higher vascular risk across a wide age range: prospective data from 574 
the Carotid Atherosclerosis Progression Study (CAPS). Stroke 2006;37:87–92. 575 
36 Polak JF, Szklo M, O'Leary DH: Associations of Coronary Heart Disease with Common 576 
Carotid Artery Near and Far Wall Intima-Media Thickness: The Multi-Ethnic Study of 577 
Atherosclerosis. J Am Soc Echocardiogr 2015;28:1114–1121. 578 
37 Lind L, Gigante B, Borne Y, Mälarstig A, Sundström J, Ärnlöv J, et al.: The plasma protein 579 
profile and cardiovascular risk differ between intima-media thickness of the common 580 
carotid artery and the bulb: A meta-analysis and a longitudinal evaluation. Atherosclerosis 581 
2020;295:25–30. 582 
38 Bots ML, Jong PTVM de, Hofman A, Grobbee DE: Left, Right, Near or Far Wall Common 583 
Carotid Intima-Media Thickness Measurements: Associations with Cardiovascular Disease 584 
and Lower Extremity Arterial Atherosclerosis. J Clin Epidemiol 1997;50:801–807. 585 
39 Iglesias del Sol A, Bots ML, Grobbee DE, Hofman A, Witteman JCM: Carotid intima-586 
media thickness at different sites: relation to incident myocardial infarction; The Rotterdam 587 
Study. Eur Heart J 2002;23:934–940. 588 
40 Tschiderer L, Klingenschmid G, Seekircher L, Willeit P: Carotid intima-media thickness 589 
predicts carotid plaque development: Meta-analysis of seven studies involving 9,341 590 
participants. Eur J Clin Invest 2020:e13217. 591 
41 Deanfield JE, Halcox JP, Rabelink TJ: Endothelial function and dysfunction: testing and 592 
clinical relevance. Circulation 2007;115:1285–1295. 593 




Figure Legends 595 
Fig. 1. Measures for quantifying atherosclerosis. 596 
 597 
Fig. 2. Data management and analysis workflow in the Proof-ATHERO consortium. 598 
 599 
Fig. 3. Location of studies contributing data to the Proof-ATHERO consortium as of 24 600 
January 2020. Full study names and references are provided in Table S1.  601 
 
 
Table 1. Availability of atherosclerosis measures in the Proof-ATHERO consortium as of  
24 January 2020 















































































General population              Clinical trials             
AIR ● ● ● ○ ○ ○  ACAPS  ● ○ ○ ○ ○ ○ 
ARIC  ● ● ● ● ● ○  ALLO-IMT  ● ○ ○ ○ ● ○ 
BRUN ● ● ● ● ○ ○  ASAP-NL  ● ● ⁕ ○ ○ ○ 
CAPS  ● ● ● ○ ○ ○  ATIC  ● ○ ○ ○ ○ ○ 
CCCC  ● ○ ● ○ ○ ○  AUDITOR  ● ○ ○ ○ ○ ○ 
CHS  ● ● ● ● ○ ○  BAS  ● ○ ○ ○ ● ○ 
CMCS-BEIJING  ● ● ● ○ ○ ○  BK REGISTRY II  ● ○ ● ○ ○ ○ 
DIWA  ● ● ⁕ ○ ○ ○  CAMERA  ● ○ ● ○ ○ ○ 
EAS  ● ○ ● ⁕ ○ ○  CAPTIVATE  ● ● ○ ○ ○ ○ 
EPICARDIAN  ● ● ○ ○ ○ ○  CERDIA  ● ○ ○ ○ ○ ○ 
EVA  ● ● ● ○ ○ ○  CONTRAST   ● ○ ● ○ ○ ○ 
HOORN  ● ⁕ ○ ⁕ ⁕ ○  EGE STUDY  ● ○ ● ○ ⁕ ⁕ 
INVADE  ● ○ ● ● ○ ○  ENHANCE  ● ○ ● ○ ○ ○ 
JHS  ● ○ ● ● ● ●  FACIT   ● ● ○ ○ ○ ○ 
KIHD  ● ○ ● ○ ○ ○  GRACE  ● ○ ⁕ ⁕ ○ ○ 
MESA  ● ⁕ ● ● ○ ●  Gresele  ● ○ ○ ⁕ ○ ○ 
NOMAS-INVEST  ● ● ● ○ ○ ○  HART  ● ○ ⁕ ⁕ ○ ○ 
PIVUS  ● ● ● ⁕ ○ ○  KIMVASC  ● ○ ○ ○ ⁕ ○ 
PLIC  ● ○ ● ○ ○ ○  LIFE-ICARUS  ● ● ● ○ ○ ○ 
ROTTERDAM  ● ● ● ⁕ ⁕ ⁕  Masia  ● ○ ● ● ○ ○ 
SAPHIR  ● ● ● ○ ○ ○  MAVET  ● ○ ○ ○ ○ ○ 
High-risk populations              MEDICLAS  ● ● ○ ○ ⁕ ○ 
BK REGISTRY  ● ○ ● ○ ○ ○  MG600  ● ● ● ○ ● ○ 
CREED ● ○ ○ ○ ○ ○  Nakamura II  ● ● ⁕ ○ ⁕ ○ 
CSN  ● ● ● ○ ○ ○  OPAL  ● ⁕ ○ ○ ○ ○ 
Ekart  ● ○ ⁕ ○ ○ ○  PERIOCARDIO  ● ● ○ ○ ⁕ ○ 
HD-IMT  ● ● ○ ○ ○ ○  PREVEND IT  ● ○ ○ ○ ○ ○ 
Honda  ● ○ ○ ○ ○ ○  RADIANCE I   ● ● ○ ○ ○ ○ 
IMPROVE  ● ● ● ○ ○ ○  RADIANCE II   ● ● ○ ○ ○ ○ 
Kato  ● ○ ● ⁕ ⁕ ○  REGRESS  ● ○ ○ ○ ○ ○ 
Landecho  ● ○ ● ○ ○ ⁕  RIS  ● ● ⁕ ○ ○ ○ 
NIGUARDA-MONZINO  ● ● ● ○ ○ ○  Safarova  ● ○ ⁕ ⁕ ⁕ ○ 
OSACA2  ● ● ○ ○ ○ ○  SECURE  ● ○ ⁕ ⁕ ○ ○ 
Papagianni  ● ○ ● ○ ○ ○  STARR  ● ○ ⁕ ⁕ ○ ○ 
POPROSTU  ● ● ○ ○ ○ ○  STOP-NIDDM  ● ○ ○ ○ ○ ○ 
RIAS  ● ○ ⁕ ○  ○ ○  VITAL  ● ○ ○ ○ ○ ○ 
SPARC  ● ○ ● ○ ○ ○  WELCOME  ● ○ ● ○ ○ ○ 
3SCO ● ● ○ ○ ○ ○         
 ● =available and provided, ⁕ =available but not provided, ○ =not available. ABI, ankle-brachial index; CACS, coronary artery 
calcium score; cIMT, carotid intima-media thickness; PWV, pulse wave velocity. Full study names and references are provided 




Table 2. Design and descriptive summary of studies in the Proof-ATHERO consortium 
Study acronym 
or first author 










General population       
AIR Sweden Population register General population 1995-97 391 0 58 (0.1) 
ARIC USA Household listings General population 1986-90 15,121 55 54 (6) 
BRUN Italy Population register General population 1990 933 49 59 (11) 
CAPS Germany Electoral rolls General population 1995-00 6,970 51 51 (13) 
CCCC Taiwan Community screening General population 1990-91 3,602 53 55 (12) 
CHS USA Medicare lists General population 1989-93 5,888 57 73 (6) 
CMCS-BEIJING China Population register General population 2002 1,324 53 60 (8) 
DIWA Sweden Population register General population 2001-04 644 100 64 (0.3) 
EAS Scotland GP lists General population 1987-88 1,115 50 64 (6) 
EPICARDIAN Spain Population register General population 1993-04 446 59 68 (12) 
EVA France Electoral rolls General population 1992-93 1,135 59 65 (3) 
HOORN Netherlands Population register General population 1999-01 780 50 69 (7) 
INVADE Germany Insurance company General population 2001-03 3,908 59 68 (8) 
JHS USA Household listings General population 2000-04 3,883 63 55 (13) 
KIHD Finland Population register General population 1987-89 1,399 0 52 (6) 
MESA USA Household listings General population 2000-02 6,814 53 62 (10) 
NOMAS-INVEST USA Random digit dialing General population 1993-01 856 62 66 (8) 
PIVUS Sweden Population register General population 2001-04 1,016 50 70 (0.0) 
PLIC Italy Hospital General population 1998-03 1,782 59 55 (11) 
ROTTERDAM Netherlands Population register General population 1990-93 7,983 61 71 (10) 
SAPHIR Austria GP lists/advert General population 1999-02 1,794 37 52 (6) 
High-risk populations       
BK REGISTRY Korea Hospital CHD 2000-07 1,000 44 60 (10) 
CREED Italy Hospital On haemodialysis/CAPD 1997-98 138 41 60 (16) 
CSN Italy GP lists Hypertension 1980-14 14,158 44 53 (13) 
Ekart Slovenia Hospital On haemodialysis 1996-05 54 50 55 (15) 
HD-IMT Serbia Hospital On haemodialysis 2004-05 85 39 59 (12) 
Honda Japan Hospital On haemodialysis 2005-07 313 39 61 (13) 
IMPROVE Multinational Hospital/community 
screening 
≥3 CVD RFs 2004-05 3,703 52 64 (5) 
Kato Japan Hospital On haemodialysis 2008-09 284 30 64 (12) 
Landecho Spain Hospital Early kidney disease 1999-11 250 12 55 (10) 
NIGUARDA-
MONZINO 
Italy Hospital Lipid clinic patients/ CVD 
RFs 
1984-10 1,564 41 56 (12) 
OSACA2 Japan Hospital ≥1 atherosclerotic RF 2000-03 291 40 65 (9) 
Papagianni Greece Hospital On haemodialysis 2001 83 46 58 (15) 
POPROSTU Poland Hospital T1DM 1999 96 33 24 (6) 
RIAS Switzerland Hospital ≥1 CVD RF/CVD 1999-00 145 43 64 (13) 
SPARC Canada Hospital Carotid plaque 2006-08 349 43 71 (9) 
3SCO Japan Hospital ≥1 CVD RF 2007 164 74 80 (6) 
Clinical trials        
ACAPS USA Mailing lists/ 
community screening 
LDL-C 130-189 mg/dL 1989-90 919 48 62 (8) 
ALLO-IMT Scotland Hospital Ischaemic stroke/TIA 2009-10 80 43 68 (10) 
ASAP-NL Netherlands Hospital Heterozygous FH 1997-98 325 61 49 (11) 
ATIC Netherlands Hospital Chronic renal failure 2001-02 93 43 53 (12) 
AUDITOR Multinational Hospital Obesity+metabolic 
syndrome 
2005-06 661 49 63 (6) 
BAS China Community screening cIMT↑ 2010 125 63 57 (5) 
BK REGISTRY II Korea Hospital Coronary stent 2000-03 205 32 60 (10) 
CAMERA Scotland Hospital/GP lists CHD 2009-11 173 23 63 (8) 
CAPTIVATE Multinational Hospital Heterozygous FH 2004-05 719 NP NP 
CERDIA Netherlands Hospital T2DM 1999-01 250 53 58 (11) 




EGE STUDY Turkey Hospital On haemodialysis 2005-06 644 46 59 (14) 
ENHANCE Multinational Hospital Heterozygous FH 2002-06 720 49 47 (9) 
FACIT Netherlands Municipal/blood bank 
registries 
General population 2000-01 819 28 60 (6) 
GRACE Multinational Hospital Dysglycaemia+CVD 
RFs/CVD 
2003-05 1,189 36 63 (8) 
Gresele Multinational Hospital Peripheral arterial disease 2003-05 442 21 67 (9) 
HART Canada Hospital/GP lists CVD/DM+≥1 CVD RF 1999-00 925 24 69 (7) 
KIMVASC Scotland GP lists CVD/hypertension/DM 2011-12 80 45 77 (5) 
LIFE-ICARUS Multinational Hospital Hypertension+LVH 1996-97 83 27 67 (6) 
Masia Spain Hospital HIV+≥2 CVD RFs 2006-07 68 10 52 (11) 
MAVET Australia Newspaper advert Smokers 1994-95 408 54 64 (6) 
MEDICLAS Multinational Hospital HIV 2003-05 48 0 42 (10) 
MG600 Brazil Hospital Hypertension 2010-11 35 100 55 (7) 
Nakamura II Japan Hospital Chronic renal failure 2001 50 40 53 (7) 
OPAL Multinational Hospital/GP lists/othera  General population 1997-99 866 100 59 (7) 
PERIOCARDIO Australia Health facilities Aboriginal Australians 2010-12 273 42 41 (10) 
PREVEND IT Netherlands Population register Microalbuminuria 1998-99 864 35 51 (12) 
RADIANCE I Multinational Hospital Heterozygous FH 2003-04 904 51 46 (13) 
RADIANCE II Multinational Hospital Mixed dyslipidaemia 2003-06 752 36 57 (8) 
REGRESS Netherlands Hospital CHD+TC 155-310 mg/dL 1989-91 255 0 56 (8) 
RIS Sweden Hospital Hypertension+≥1 CVD RF 1987-89 164 0 66 (5) 
Safarova Russia Hospital CHD 2007-09 60 0 55 (6) 
SECURE Canada Hospital CVD/DM+≥1 CVD RF 1994-95 731 24 66 (7) 
STARR Multinational Hospital/GP lists/otherb Dysglycaemia 2001-03 1,320 55 53 (11) 
STOP-NIDDM Germany High-risk population 
screening  
Dysglycaemia 1996-98 119 42 54 (7) 
VITAL Netherlands Hospital Indication for statin use 2002-04 199 41 49 (12) 
WELCOME UK Hospital NAFLD 2010-11 103 42 51 (11) 
Total    1980-14 106,846 50 59 (10) 
CAPD, continuous ambulatory peritoneal dialysis; CHD, coronary heart disease; cIMT, carotid intima-media thickness; CVD, 
cardiovascular disease; DM, diabetes mellitus; FH, familial hypercholesterolaemia; GP, general practitioner; HIV, human 
immunodeficiency virus; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; LDL-C, low-density lipoprotein 
cholesterol; LVH, left ventricular hypertrophy; NAFLD, non-alcoholic fatty liver disease; NP, not provided; RF, risk factor; SD, 
standard deviation; TC, total cholesterol; TIA, transient ischaemic attack; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes 
mellitus. Full study names and references are provided in Table S1. aExisting ongoing population-based cohorts and advertisements 
in local print and broadcast media. bPublic advertising and news reports in the media, internet items, referral from relatives, poster 
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Table S1. Study acronyms, full study names, and study references in the Proof-ATHERO 
consortium 
Study acronym or first 
author 
Ref. Full study name 
General population   
AIR [1] Atherosclerosis and Insulin Resistance Study 
ARIC [2] Atherosclerosis Risk in Communities Study 
BRUN [3] Bruneck Study 
CAPS [4] Carotid Atherosclerosis Progression Study 
CCCC [5] Chin-Shan Community Cardiovascular Cohort 
CHS [6] Cardiovascular Health Study 
CMCS-BEIJING [7] Chinese Multi-Provincial Cohort Study (Beijing) 
DIWA [8] Diabetes and Insulin Resistance in Women Study 
EAS [9] Edinburgh Artery Study 
EPICARDIAN [10] Epidemiología Cardiovascular en los Ancianos en España Study 
EVA [11] Étude sur la Vieillissement Artériel Study 
HOORN [12] Hoorn Study 
INVADE [13] Interventionsprojekt zerebrovaskuläre Erkrankungen und Demenz im Landkreis 
Ebersberg 
JHS [14] Jackson Heart Study 
KIHD [15] Kuopio Ischemic Heart Disease Risk Factor Study 
MESA [16] Multi-Ethnic Study of Atherosclerosis 
NOMAS-INVEST [17] Northern Manhattan Study and The Oral Infections and Vascular Disease 
Epidemiology Study 
PIVUS [18] Prospective Investigation of the Vasculature in Uppsala Seniors Study 
PLIC [19] Presence and Progression of Lesions in Carotid Arteries Study 
ROTTERDAM [20] Rotterdam Study 
SAPHIR [21] Salzburg Atherosclerosis Prevention Program in Subjects at High Individual Risk 
High-risk populations   
BK REGISTRY [22] BK Registry Study 
CREED [23] Cardiovascular Risk Extended Evaluation in Dialysis Patients 
CSN [24] Campania Salute Network 
Ekart [25] Study Ekart et al. 
HD-IMT [26] HD-IMT Study 
Honda [27] Study Honda et al. 
IMPROVE [28] Carotid Intima Media Thickness and IMT-Progression as Predictors of Vascular 
Events in a High Risk European Population Study 
Kato [29] Study Kato et al. 
Landecho [30] Study Landecho et al. 
NIGUARDA-MONZINO [31] Niguarda-Monzino Study 
OSACA2 [32] Osaka Follow-up Study for Carotid Atherosclerosis 2 
Papagianni [33] Study Papagianni et al. 
POPROSTU [34] Poznań Prospective Study of Type-1 Diabetic Patients 
RIAS [35] Resistive Index in Atherosclerosis Study 
SPARC [36] SPARC Study 
3SCO [37] Hiroshima-Shobara-Soryo Cohort 
Clinical trials   
ACAPS [38] Asymptomatic Carotid Artery Progression Study 
ALLO-IMT [39] ALLO-IMT Study 
ASAP-NL [40] Atorvastatin vs. Simvastatin on Atherosclerosis Progression Study 
ATIC [41] Anti-oxidant Therapy in Chronic Renal Insufficiency Study 
AUDITOR [42] Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in 
atients on Rimonabant Study 
BAS [43] Beijing Atherosclerosis Study 
BK REGISTRY II [44] BK Registry II Study 
CAMERA [45] Carotid Atherosclerosis - Metformin for Insulin Resistance Study 
CAPTIVATE [46] Carotid Atherosclerosis Progression Trial Investigating Vascular ACAT Inhibition 
CERDIA [47] Cerivastatin in Diabetes Trial 
CONTRAST [48] Convective Transport Study 




ENHANCE [50] Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis 
egression Trial 
FACIT [51] Folic Acid and Carotid Intima-media Thickness Study 
GRACE [52] Glucose Reduction and Atherosclerosis Continuing Evaluation Study 
Gresele [53] Study Gresele at al. 
HART [54] Homocysteine and Atherosclerosis Reduction Trial 
KIMVASC [55] KIMVASC Study 
LIFE-ICARUS [56] Losartan Intervention For Endpoint Reduction in Hypertension - Insulin Carotids US 
Scandinavia Study 
Masia [57] Study Masiá et al. 
MAVET [58] Melbourne Atherosclerosis Vitamin E Trial 
MEDICLAS [59] Metabolic Effects of Different Classes of Antiretrovirals Study 
MG600  [60] Effects of Magnesium Supplementation on Vascular Structure and Function in 
Hypertensive Patients Study 
Nakamura II [61] Study Nakamura et al. II 
OPAL [62] Osteoporosis Prevention and Arterial Effects of Tibolone Study 
PERIOCARDIO [63] PerioCardio Study 
PREVEND IT [64] Prevention of Renal and Vascular Endstage Disease Intervention Trial 
RADIANCE I [65] Rating Atherosclerosis Disease Change by Imaging with a New CETP Inhibitor 1 
Trial 
RADIANCE II [66] Rating Atherosclerosis Disease Change by Imaging with a New CETP Inhibitor 2 
Trial 
REGRESS [67] Regression Growth Evaluation Statin Study 
RIS [68] Risk Factor Intervention Study 
Safarova [69] Study Safarova at al. 
SECURE [70] Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and 
Vitamin E 
STARR [71] Study of Atherosclerosis with Ramipril and Rosiglitazone 
STOP-NIDDM [72] Study to Prevent Non-Insulin-Dependent Diabetes Mellitus 
VITAL [73] Vital Study 
WELCOME [74] Wessex Evaluation of Fatty Liver and Cardiovascular Markers in NAFLD with 





Table S2. Ascertainment of cIMT in the Proof-ATHERO consortium 
Study acronym or first 
author 
cIMT definition  Measurement features  









































































































































General population                                           
AIR ● ● ○  ● ● ●  ○ ● ●  ● ●  – – + + + + – +e 
ARIC ● ● ●  ● ● ●  ● ● ●  ● ●  – + + + – + + – 
BRUN ● ● ●  ● ● ●  ○ ● ●  ● ●  + – + – + – + – 
CAPS ● ● ●  ● ● ●  ○ ● ●  ● ○  – – + + – + – +d 
CCCC ● ○ ●  ● ● ●  ○ ● ●  ○ ●  + + + + – – + – 
CHS ● ○ ●  ● ● ●  ● ● ●  ○ ●  – +a – + – + + – 
CMCS-BEIJING ● ● ●  ● ● ●  ○ ○ ●  ● ●  + – – – – + + –/+e 
DIWA ● ● ○  ● ● ●  ○ ● ●  ● ●  – – + + + + – +e 
EAS ● ○ ○  ● ● ●  ○ ● ●  ● ●  – – – + – + – – 
EPICARDIAN ● ● ●  ● ● ●  ○ ● ●  ● ○  + + – + + – + – 
EVA ● ○ ○  ● ● ●  ○ ● ●  ● ○  + – – + – + + +d 
HOORN ● ○ ○  ● ○ ●  ○ ● ●  ● ○  + + + + + + + +d 
INVADE ● ○ ○  ● ● ●  ○ ● ●  ● ○  + + – + + + + +d 
JHS ● ● ●  ● ● ●  ● ● ●  ● ●  – + + + – + + – 
KIHD ● ○ ○  ● ● ●  ○ ● ●  ● ●  – – – – – + + + e 
MESA ● ○ ●  ● ● ●  ○ ○ ●  ● ●  + +ab + + NR + + +d 
NOMAS-INVEST ● ● ●  ● ● ●  ● ● ●  ● ●  + +b – + + + + + e 
PIVUS ● ○ ○  ● ● ●  ○ ● ●  ● ●  NR – + + + + – +e 
PLIC ● ○ ○  ● ● ●  ○ ● ●  ● ●  + +b + + + + – + 
ROTTERDAM ● ○ ○  ● ● ●  ● ● ●  ● ●  – + + + – + – – 
SAPHIR ● ● ●  ● ● ●  ○ ○ ●  ● ○  + + – + + + + – 
High-risk populations                                           
BK REGISTRY ● ● ○  ● ● ●  ○ ● ●  ● ○  + + + + + + + +e 
CREED ● ○ ○  ○ ○ ●  ○ ● ●  ● ○  + – + + + – + – 
CSN ● ● ●  ● ● ●  ● ● ●  ○ ●  – – – + – + – – 
Ekart ● ● ●  ● ● ●  ○ ● ●  ● ○  + + – + + + + – 
HD-IMT ● ○ ○  ● ○ ●  ○ ● ●  ○ ●  – – + + + – – – 
Honda ● ○ ○  ● ● ●  ○ ● ●  ● ●  – – – – – – – – 
IMPROVE ● ● ●  ● ● ●  ○ ● ●  ● ●  – + +b + – + + +e 
Kato ● ○ ○  ○ ○ ●  ○ ● ●  ● ●  + – – + + + + +e 
Landecho ● ○ ○  ● ● ●  ○ ○ ●  ○ ●  + – – – – – – – 
NIGUARDA-MONZINO ● ● ●  ● ● ●  ● ● ●  ○ ●  – – – – – – + – 
OSACA2 ● ● ●  ● ● ●  ● ● ●  ● ●  – +b – + – + – – 
Papagianni ○ ● ○  ● ● ●  ○ ● ●  ● ●  + – + + + + – – 
POPROSTU ● ○ ○  ● ○ ●  ○ ● ●  ● ●  + + – + + + + +d 
RIAS ● ○ ○  ● ● ●  ○ ● ●  ● ○  + + + + – – – – 
SPARC ● ○ ○  ● ● ●  ○ ● ●  ● ○  + + – NR NR + – – 
3SCO ● ● ●  ● ● ●  ● ● ●  ● ●  – – – + – – – – 
Clinical trials                                           
ACAPS ● ● ●  ● ● ●  ○ ○ ●  ○ ●  – – + + – + + +e 
ALLO-IMT ● ● ●  ● ● ●  ● ● ●  ● ●  – – + + + + + +de 
ASAP-NL ● ● ●  ● ● ●  ● ● ●  ● ○  – – – + – + + +e 
ATIC ● ○ ○  ● ○ ●  ○ ● ●  ● ○  + + + + + + – +d 
AUDITOR ● ● ●  ● ● ●  ○ ● ●  ● ○  – – + + – + + – 
BAS ● ○ ○  ○ ○ ●  ● ○ ●  ● ○  + – – + – + – – 
BK REGISTRY II ● ● ●  ○ ● ●  ○ ● ●  ● ○  + + + + + + + +e 
CAMERA ● ○ ○  ● ● ●  ○ ● ●  ● ○  + – + + + + + +e 
CAPTIVATE ● ● ●  ● ● ●  ● ● ●  ● ●  – + – + – + + +e 
CERDIA ● ● ●  ● ○ ●  ○ ○ ●  ● ●  + – + + – + + +e 




EGE STUDY ● ○ ○  ● ● ●  ○ ● ●  ● ○  + NR NR + + NR NR NR 
ENHANCE ● ● ●  ● ● ●  ○ ● ●  ● ●  – +c – + – + + +e 
FACIT ● ○ ○  ○ ○ ●  ○ ○ ●  ● ●  – + + + – + + +d 
GRACE ● ● ●  ● ● ●  ● ● ●  ● ●  – + – – – + + – 
Gresele ● ○ ○  ● ○ ●  ● ○ ●  ● ●  + – – + + + + +d 
HART ● ● ●  ● ● ●  ● ● ●  ● ●  – + – – – + + – 
KIMVASC ● ○ ○  ● ● ●  ○ ● ●  ● ○  + – – + + + – – 
LIFE-ICARUS ● ○ ○  ● ● ●  ○ ● ●  ● ○  + +b + + + + + +e 
Masia ● ○ ○  ● ● ●  ○ ● ●  ● ●  NR NR NR NR NR NR NR NR 
MAVET ● ○ ○  ○ ○ ●  ○ ○ ●  ○ ●  NR + + + + + + – 
MEDICLAS ● ○ ○  ● ○ ●  ○ ○ ●  ● ○  + + – + + + – – 
MG600 ● ○ ○  ● ● ●  ○ ○ ●  ● ●  + + + + + – – – 
Nakamura II ● ● ●  ● ● ●  ○ ● ●  ● ●  + – + + + + + – 
OPAL ● ● ●  ● ● ●  ● ● ●  ● ●  – + + + – + + – 
PERIOCARDIO ● ○ ○  ● ● ●  ○ ● ●  ● ●  – + + + – + + +e 
PREVEND IT ● ○ ○  ○ ● ●  ○ ● ●  ● ○  + + + + – + + +d 
RADIANCE I ● ● ●  ● ● ●  ● ● ●  ● ●  – +c + + – + + +e 
RADIANCE II ● ● ●  ● ● ●  ● ● ●  ● ●  – +c + + – + + +e 
REGRESS ● ● ●  ● ● ●  ● ● ●  ● ●  – – – – – + + +d 
RIS ● ● ○  ● ○ ●  ○ ● ●  ● ●  + + + + + + + +d 
Safarova ● ○ ○  ● ● ●  ○ ● ●  ● ○  + – + + + + + +e 
SECURE ● ● ●  ● ● ●  ● ● ●  ○ ●  – + – – – + + – 
STARR ● ● ●  ● ● ●  ● ● ●  ● ●  – + – – – + + – 
STOP-NIDDM ● ○ ○  ● ● ●  ○ ● ●  ● ●  NR + + + – NR NR NR 
VITAL ● ○ ○  ● ○ ●  ○ ● ●  ● ○  NR NR NR NR NR NR NR NR 
WELCOME ● ○ ○  ● ● ●  ○ ● ●  ● ○  + + + + + + + +d 
 ● =provided, ○ =not provided; BIF=carotid bifurcation, CCA=common carotid artery, cIMT=carotid intima-media thickness, 
ECG=electrocardiography, ICA=internal carotid artery, IMT=intima-media thickness. Full study names and references are 





Table S3. Ascertainment of carotid plaque in the Proof-ATHERO consortium 
Study acronym or first 
author 
Parameters 




























General population             
AIR ● ● ● ● ● Distinct area with an IMT >50% thicker than that of neighbouring sites 
ARIC ● ● ○ ○ ○ If two of three conditions are met: (1) wall shape (protrusion into the lumen, 
loss of alignment, rough boundary), (2) wall texture (brighter echoes than 
adjacent boundaries), and (3) wall thickness (IMT ≥1.5 mm) 
BRUN ● ● ● ○ ○ Based on (1) wall surface (protrusion into the lumen or roughness of the 
arterial boundary) and (2) wall texture (echogenicity) 
CAPS ● ○ ○ ○ ○ Focal protrusion of ≥1.8 mm 
CCCC ● ● ○ ○ ○ Grading as (1) normal or no observable plaque, (2) one small plaque with 
diameter stenosis <30%, (3) one medium plaque with 30-49% diameter 
stenosis or multiple small plaques, (4) one large plaque with 50-99% 
diameter stenosis or multiple plaques with at least one medium plaque, and 
(5) 100% occlusion 
CHS ● ○ ○ ○ ● Definition based on the greatest wall protrusion (i.e. IMT) and grading based 
on lesion surface, echogenicity, and texture characteristics as (1) no plaque 
(i.e. smooth surface and normal density and morphology), (2) high-risk 
plaque (i.e. irregular/ulcerated surface, echolucent, or heterogeneous texture), 
and (3) intermediate-risk plaque (i.e. any other combinations of lesion 
characteristics)  
CMCS-BEIJING ● ○ ● ● ○ IMT ≥1.3 mm or focal structure encroaching into arterial lumen of ≥0.5 mm 
or ≥50% of surrounding IMT 
EAS ● ○ ● ○ ○ IMT >1.2 mm with advanced atherosclerotic plaque defined as IMT >2 mm 
EVA ● ● ● ○ ○ Localised echo structures encroaching into the vessel lumen with a distance 
≥1 mm between media-adventitia interface and lesion surface facing the 
lumen 
INVADE ● ○ ○ ○ ○ Focal structure encroaching into the arterial lumen ≥0.5 mm or ≥50% of the 
surrounding IMT, or IMT >1.5 mm as measured from the media-adventitia 
interface to the intima-lumen interface 
JHS ● ○ ○ ○ ○ If two of three conditions are met: (1) wall shape (protrusion into the lumen, 
loss of alignment, rough boundary), (2) wall texture (brighter echoes than 
adjacent boundaries), and (3) wall thickness (IMT ≥1.5 mm) 
KIHD ● ○ ○ ○ ○ Distinct area either with mineralisation (bright echo, often producing a 
typical echogenic shadow) or with focal protrusion into the lumen 
MESA ● ○ ○ ○ ● Discrete, focal thickening ≥1.5 mm or ≥50% greater than the surrounding 
IMT 
NOMAS-INVEST ● ● ● ● ○ Focal wall thickening or protrusion into the lumen >50% greater than the 
surrounding thickness 
PIVUS ● ○ ● ● ○ Local thickening of the intima-media by >50% vs. surrounding IMT 
PLIC ● ○ ○ ○ ○ Focal plaque >1.3 mm in longitudinal resolution, lateral, or medial angle 
ROTTERDAM ● ○ ○ ○ ○ Focal widening relative to adjacent segments, with protrusion into the lumen 
with calcified deposits or both calcified and non-calcified material 
SAPHIR ● ○ ○ ○ ○ Grading as (1) normal, (2) vessel wall thickening <1 mm, (3) one minimal 
plaque ≤2 mm, (4) two moderate plaques ≤3 mm, (5) severe plaque >3 mm, 
and (6) completely obstructed lumen 
High-risk populations             
BK REGISTRY ● ○ ● ○ ○ Focal structure encroaching into arterial lumen by ≥50% of surrounding IMT 
or thickness >1.2 mm 
CSN ● ○ ○ ○ ○ IMT >1.5 mm 
IMPROVE ● ● ● ● ○ IMT ≥1.5 mm 
Kato ● ○ ○ ○ ○ IMT >1 mm 
Landecho ● ○ ○ ○ ○ Echogenic structures encroaching on the vessel’s lumen with a distinct area 
50% greater than the IMT of neighbouring sites 
NIGUARDA-MONZINO ● ● ● ○ ○ IMT ≥1.5 mm 
Papagianni ● ○ ○ ○ ○ Faint grey echoes or bright white echoes protruding into the arterial lumen 
SPARC ● ○ ○ ● ○ Focal thickening >1 mm 
Clinical trials             
BK REGISTRY II ● ○ ● ○ ○ Localised thickening >1.2 mm not involving the whole carotid artery 




CONTRAST ● ● ○ ○ ○ Grading as (1) no plaque, (2) minimal plaque, (3) moderate plaque, and (4) 
severe plaque, where a moderate or severe plaque was generally defined as a 
focal structure that encroaches into the arterial lumen or demonstrates a 
thickness >1.5 mm 
EGE STUDY ● ○ ● ○ ○ NR 
ENHANCE ● ○ ○ ○ ○ IMT >1.3 mm 
LIFE-ICARUS ● ○ ○ ○ ○ Semi-quantitative grading of the amount of atherosclerotic lesions as (1) 
none, (2) very few, (3) few, (4) some, and (5) several 
Masia ● ○ ○ ○ ○ NR 
MG600 ● ○ ○ ○ ○ IMT ≥1.5 mm 
WELCOME ● ○ ○ ○ ○ Focal thickening ≥50% greater than the surrounding wall or focal region with 
IMT >1.5 mm protruding into the lumen distinct from adjacent boundary 
 ● =provided, ○ =not provided; IMT, intima-media thickness; NR, not reported. Full study names and references are provided 





Table S4. Assessment of prevalent and incident disease in the Proof-
ATHERO consortium 
Study acronym or first 
author 
Prevalent disease  Incident events 
CHD Stroke Diabetes  CHD Stroke Death 
General population        
AIR + + ++   ++ ++ * 
ARIC ++ ++ ++   ++ ++ ** 
BRUN ++ ++ ++  ++ ++ ** 
CAPS + + +   ++ ++ ** 
CCCC ++ ++ ++   NR ++ * 
CHS ++ ++ ++   ++ ++ ** 
CMCS-BEIJING ++ ++ ++   ++ ++ **c 
DIWA + + ++   ++ ++ * 
EAS ++ + +   ++ ++ **c 
EPICARDIAN ++ ++ ++   ++ ++ * 
EVA + + ++   ++b ++b ** 
HOORN +/++ +/++ ++   ++ ++ ** 
INVADE ++ ++ ++   ++ ++ ** 
JHS + + ++   + + –a 
KIHD ++ + ++   ++ ++ ** 
MESA + –a ++   ++ ++ ** 
NOMAS-INVEST + + ++   ++ ++ ** 
PIVUS + + +/++   ++ ++ ** 
PLIC NR NR ++   NR NR NR 
ROTTERDAM ++ ++ ++   ++ ++ ** 
SAPHIR ++ ++ ++   ++ ++ ** 
High–risk populations         
BK REGISTRY ++ – ++   ++ ++ */** 
CREED NR NR NR  ++ ++ ** 
CSN ++ ++ ++   ++ ++ ** 
Ekart NR – NR   NR NR NR 
HD-IMT NR NR NR   NR NR NR 
Honda NR ++ NR   ++b ++b ** 
IMPROVE ++ ++ ++   ++ ++ ** 
Kato ++ ++ ++   ++ ++ ** 
Landecho ++ ++ ++   ++ ++ ** 
NIGUARDA-MONZINO ++ ++ ++   ++ ++ ** 
OSACA2 + + ++   ++ ++ * 
Papagianni ++ + ++   ++ + */** 
POPROSTU ++ + ++   ++ ++ * 
RIAS ++ ++ ++   ++ ++ ** 
SPARC NR NR NR   ++ ++ ** 
3SCO ++ ++ ++   ++ ++ ** 
Clinical trials         
ACAPS + + +   ++ ++ ** 
ALLO-IMT + ++ +   ++ ++ * 
ASAP-NL – – ++   – – – 
ATIC +/++ +/++ +/++   –a –a –a 
AUDITOR – – ++   – – – 
BAS + + +   – + – 
BK REGISTRY II ++ – ++   ++ ++ */** 
CAMERA ++ + ++   ++ ++ ** 
CAPTIVATE – – ++   – – – 
CERDIA ++ – ++   ++ ++ ** 
CONTRAST + + +   ++ ++ ** 
EGE STUDY NR NR NR  ++ ++ ** 
ENHANCE –a ++ ++   ++ ++ ** 
FACIT + + +   – – * 
GRACE ++ ++ ++   ++ ++ ** 
Gresele ++ ++ ++   ++ ++ ** 
HART ++ ++ ++   ++ ++ ** 




LIFE-ICARUS ++ ++ ++   ++ ++ ** 
Masia NR NR ++   NR – NR 
MAVET –a –a –a   – – – 
MEDICLAS – – –   + + * 
MG600 ++ ++ ++   ++ ++ ** 
Nakamura II NR NR NR   NR NR NR 
OPAL + + +   + + * 
PERIOCARDIO + + +   + + ** 
PREVEND IT + –a +   ++ ++ * 
RADIANCE I + – ++   ++ ++ ** 
RADIANCE II + – ++   ++ ++ ** 
REGRESS ++ – ++   –a –a –a 
RIS ++ ++ ++   ++ ++ ** 
Safarova ++ ++ ++   ++ ++ * 
SECURE ++ ++ ++   ++ ++ ** 
STARR ++ ++ ++   ++ ++ ** 
STOP-NIDDM ++ NR ++   ++ ++ NR 
VITAL + + ++   ++ ++ ** 
WELCOME ++ ++ ++   ++ ++ ** 
–, not provided; +, self-report only; ++, self-report supplemented by objective criteria (e.g.: 
electrocardiography, echocardiography, enzymes, imaging); *, based on death certificate only; **, 
based on death certificate supplemented by medical record; CHD, coronary heart disease; NR, not 
reported; Full study names and references are provided in Table S1. arecorded but not provided. 
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